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Prognostic signiﬁcance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated
histone H4 in cutaneous T-cell lymphoma
Aims: Aberrant histone acetylation has been associated
with malignancy and histone deacetylase (HDAC) inhib-
itorsarecurrentlybeinginvestigatedinnumerousclinical
trials. So far, the malignancy most sensitive to HDAC
inhibitors has been cutaneous T-cell lymphoma (CTCL).
The reason for this sensitivity is unclear and studies on
HDAC expression and histone acetylation in CTCL are
lacking. The aim of this study was to address this issue.
Methods and results: The immunohistochemical expres-
sionofHDAC1,HDAC2,HDAC6,andacetylated H4was
examined in 73 CTCLs and the results related to histo-
logical subtypes and overall survival. HDAC1 was most
abundantlyexpressed(P < 0.0001),followedbyHDAC2;
HDAC6 and H4 acetylation were equally expressed.
HDAC2 (P = 0.001) and H4 acetylation (P = 0.03)
were signiﬁcantly more common in aggressive than
indolent CTCL subtypes. In contrast, no differences were
observed for HDAC1 and HDAC6. In a Cox analysis,
elevated HDAC6 was the only parameter showing
signiﬁcant inﬂuence on survival (P = 0.04).
Conclusions: High expression of HDAC2 and acetylated
H4 is more common in aggressive than indolent CTCL.
HDAC6 expression is associated with a favorable
outcome independent of the subtype.
Keywords:acetylation,cutaneousT-celllymphoma,histonedeacetylases,histoneH4,immunohistochemistry,survival
Abbreviations: ALCL, anaplastic large cell lymphoma; BSA, bovine serum albumin; CR, complete response;
CTCL, cutaneous T-cell lymphoma; HAT, histone acetyltransferase; HDAC, histone deacetylase; HR, hazard ratio;
MF, mycosis fungoides; NOS, not otherwise speciﬁed; PR, partial response; PTL, peripheral T-cell lymphoma;
SS, Se ´zary syndrome; TBS, Tris-buffered saline
Introduction
Cutaneous T-cell lymphomas (CTCL) are a hetero-
geneous group of non-Hodgkin’s lymphomas deﬁned by
clonal proliferation of skin-homing malignant T lym-
phocytes. CTCL vary from indolent subtypes such as
plaque lesions of mycosis fungoides (MF) to more
aggressive phenotypes, such as Se ´zary syndrome (SS)
and CD30) peripheral T-cell lymphomas. Survival
rates are signiﬁcantly different between patients with
indolent and aggressive phenotypes. Hence, the 5-year
survival rate for indolent CTCL is 90%
1–3 compared
with a <33% 5-year survival rate for aggressive
CTCL.
1–3
Whereas early MF is well controlled by skin-directed
therapies or phototherapy,
4–9 patients with more aggres-
sive subtypes require systemic therapy. Interferons,
Address for correspondence: L Marquard, Experimental Pathology
Unit, Department of Pathology, Copenhagen Biocentre, Copenhagen
University Hospital 3731, Ole Maaloees vej 5, DK-2200 Copenhagen
N, Denmark. e-mail: lmi@topotarget.com
Re-use of this article is permitted in accordance with the Creative
Commons Deed, Attribution 2.5, which does not permit commercial
exploitation.
  2008 The Authors. Journal compilation   2008 Blackwell Publishing Limited.
Histopathology 2008, 53, 267–277. DOI: 10.1111/j.1365-2559.2008.03109.xretinoids, single-agent or combined chemotherapy
have been used,
10,11 but relapses are frequent
12,13
and most drugs have not improved long-term sur-
vival.
10,11,14,15 New therapies are thus needed for
treating CTCL.
Histone deacetylase (HDAC) inhibitors are a prom-
ising group of drugs in the treatment of both solid and
haematological malignancies. By targeting of HDAC
enzymes,
16 they cause acetylation of core histones and
other proteins.
17 HDAC inhibitors can either be pan-
inhibitors that target all 11 isoforms of HDAC enzymes,
or selective inhibitors that target speciﬁc isoforms
or subclasses of HDAC.
18 HDACs are, together with
histone acetyltransferases (HATs), involved in the
regulation of transcriptional activity through acetyl-
ation and deacetylation of speciﬁc lysine residues on
core histones. In general, histone acetylation through
HAT activity leads to increased transcriptional activity,
whereas deacetylation through HDAC activity leads
to transcriptional repression.
19,20 HDACs are over-
expressed in many malignancies
21–25 and are believed
to participate in malignant transformation through
transcriptional repression of tumour suppressor
genes.
25–27 HDACs normally function together with
cofactors that recruit HDACs to target genes
28 and
improper recruitment of HDACs by these cofactors
has been identiﬁed as a mechanism for the develop-
ment of malignancy.
29,30 Fusion proteins generated by
chromosomal translocations have also shown impro-
per HDAC recruitment, particularly in leukaemia.
Although the exact anti-tumour mechanisms of action
of HDAC inhibitors are unknown, they have been
shown to induce cell cycle arrest, proliferation and
apoptosis in neoplastic cells.
31–36
For unknown reasons, CTCL has been the malignant
disease with the highest clinical response so far to HDAC
inhibitors.Thus,allthreesmallmoleculehydroxamates,
vorinostat(SAHA),panobinostat(LBH-589)andbelino-
stat(PXD101),aswellasthenaturalproductromidepsin
(depsipeptide), have demonstrated response rates above
24% in CTCL,
37 and vorinostat has been approved by
the Food and Drug Administration for this indication
as Zolinza
TM (http://www.fda.gov/bbs/topics/NEWS/
2006/NEW01484.html).
Despite this marked sensitivity of CTCL to HDAC
inhibitors, studies on HDAC expression in CTCL are
lacking. The aim of this study was to improve our
understanding of HDAC involvement in the develop-
ment of CTCL. Thus, we examined the expression of
HDAC1, HDAC2 and HDAC6 together with the acetyl-
ation of histone H4 in CTCL tissue samples and
correlated these results with the histological subtype
and clinical outcome.
Materials and methods
patients and tissue samples
Formalin-ﬁxed parafﬁn-embedded samples from skin
lesions from 73 patients diagnosed with primary CTCL
during the period 1979–2004 were drawn from the
archives of the Department of Pathology, Copenhagen
University Hospital. None of the patients participated in
clinical trials for HDAC inhibitors. The clinical records
were reviewed and all samples were examined by
morphology and immunohistochemistry, using as a
minimum CD3, CD5, CD4, CD8, CD56 and CD30.
Based upon these data, the specimens were reclassiﬁed
according to the World Health Organization-European
Organization for Research and Treatment of Cancer
classiﬁcation and comprised 32 cases of MF with
plaque lesions, seven cases of MF with tumour lesions,
ﬁve cases of MF with transformation to large T-cell
lymphoma, four cases of SS, seven cases of CD30+
primary cutaneous anaplastic large cell lymphoma
(ALCL), 12 cases of CD30) peripheral T-cell lymphoma
(PTL) not otherwise speciﬁed (NOS), two cases of
extranodal natural killer ⁄ T-cell neoplasm, nasal type
and four cases classiﬁed as precursor plasmacytoid
dendritic cell neoplasm. These cases were grouped into
two categories, i.e. indolent CTCL, comprising MF
plaque, MF tumour and CD30+ large cell lymphoma;
and aggressive CTCL, comprising the remaining disease
categories.
Information on the clinical outcome could be
retrieved in 59 (80.1%) of the cases. The overall
survival for these patients ranged from 1 to
360 months, with large variations within each cate-
gory (Table 1).
control cell lines
The A2780 human ovarian cancer cell line (gift from
Dr R. Ozols, Fox Chase Cancer Ctr. Philadelphia, PA,
USA) was used as the positive control in the immuno-
histochemical analyses. Thus, A2780 cells treated with
1 lm belinostat (TopoTarget A ⁄ S, Copenhagen, Den-
mark) for 24 h were used as the positive control for H4
acetylation, whereas untreated A2780 cells were used
as negative controls for the absence of H4 acetylation.
The P388 murine leukaemia cell line, (gift from F. M.
Shabel, SRI, Birmingham, AL, USA) together with a
clone of P388 lacking HDAC2 (P388 ⁄ 2C clone 1) was
used as the control for HDAC2 expression. Untreated
A2780 cells were used as positive controls for reactivity
of anti-HDAC1 and anti-HDAC6. Negative controls
were performed by substituting the speciﬁc antibodies
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saline (TBS) (pH 7.6).
tests for antibody specificity
Primary antibodies were monoclonal anti-HDAC1
(Upstate, Temecula, CA, USA; 05-614), monoclonal
anti-HDAC2 (Abcam, Cambridge, MA, USA; ab12169),
polyclonal anti-HDAC6 (Abcam; ab1440) and mono-
clonal anti-acetylated H4 (clone T25 developed by
Ronzoni et al.
38). An initial test for antibody speciﬁcity
was performed by Western blotting using either whole-
cell lysates or histones puriﬁed from P388 cells after
treatment with 1 lm belinostat for 1 h. Blots were
incubated with each of the primary antibodies before
development. The appearance of only one band veriﬁed
antibody speciﬁcity. The speciﬁcity of each anti-HDAC
antibody was further tested in an immunohistochem-
ical absorption assay against the corresponding HDAC
peptide (gift from CuraGen Corporation, Branford, CT,
USA). The antibody was incubated with excess amount
of peptide prior to immunohistochemical analysis.
Immunonegativity was then considered to be ﬁnal
proof of antibody speciﬁcity.
immunohistochemical analysis
Heat-induced epitope retrieval was performed using
Tris-hydrochloride (TEG) buffer pH 9 (10 mm Tris-HCl +
0.5 mm ethylene glycol tetraacetic acid) for retrieval
of HDAC1, HDAC6, and acetylated H4 or Target
Retrieval Solution, Citrate pH 6 (Dako, Glostrup, Den-
mark; S2369) for retrieval of HDAC2. Peroxidase
Blocking Reagent (Dako; S2001) was used for blocking
endogen peroxidase activity. Slides were pre-incubated
in 2% BSA in TBS (pH 7.6) before primary antibodies
were added. Dilution of primary antibodies was:
anti-HDAC1 (1:2000), anti-HDAC2 (1:12 000), anti-
HDAC6 (1:50) and anti-acetylated H4 (1:13 000).
EnVision+ (Dako; K4001 ⁄ K4003) and diaminobenzid-
ene (DAB)+ (Dako; K3468) were used as the detection
system. Slides were counterstained with Mayer’s hae-
matoxylin.
Scoring of immunohistochemistry was based on two
parameters: the number of immunopositive tumour
cells and their intensity of immunoreactivity. Four
different scores were given for the number of positive
tumour cells, i.e. 0, <5%; 1, >5% to £20%; 2, >20%
to £50%; and 3, >50% positive cells. Intensity of
positivity was given a score of 0 for no positivity, 1 for
weak positivity, 2 for moderate positivity and 3 for
strong positivity. The sum of the two individual scores
deﬁned the ﬁnal immunoreactivity score of each
sample, ending up with seven groups with scores
between 0 and 6. Finally, in order to ensure a
sufﬁcient number of samples in each group for
statistical analysis, the samples were grouped in three
expression categories deﬁned as low (score 0–2),
moderate (score 3 and 4) or high (score 5 and 6)
expression. All reactions were simultaneously scored
by two observers (L.M., E.R.) using a double-headed
microscope.
statistical analyses
The comparison of the probability of expression of
HDAC1, HDAC2, HDAC6 and acetylated H4 was done
using a repeated measures linear model with ordi-
nal categorical data. Tests for independence between
immunohistochemical data and diagnostic groups were
done using the chi-squared test with exact probabilities.
Spearman rank correlation was calculated as a mea-
sure of association between the HDACs and H4
acetylation. Survival was calculated from the day of
diagnosis until death or last follow-up. Survival prob-
abilities were estimated by the Kaplan–Meier method
and the log rank statistic was used to compare survival
curves. Multivariate analysis of protein expression
Table 1. Clinical data from 59 cutaneous T-cell lymphoma
(CTCL) patients showing number of patients, range in overall
survival and median survival within each CTCL category
Subtype N
OS
(months)
Median
(months)
Indolent categories
Mycosis fungoides,
plaque stage
27 2–360 117
Mycosis fungoides,
tumor stage
6 2–120 61.5
CD30+ c-ALCL* 4 5–120 19.5
Total 37 2–360 84.0
Aggressive categories
Mycosis fungoides,
transformed
5 48–182 60
Se ´zary syndrome 3 30–240 192
PTL, NOS† 8 5–36 20
NK ⁄ T-cell lymphoma 2 1 1
PPDCN‡ 4 12–30 25
Total 22 1–240 28.5
*Primary cutaneous anaplastic large cell lymphoma.
†Peripheral T-cell lymphoma, not otherwise speciﬁed.
‡Precursor plasmacytoid dendritic cell neoplasm.
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using the Cox proportional hazards model. P-values
<5% were considered to be signiﬁcant.
ethical aspects
This study was approved by the local ethics committee
in Copenhagen, Denmark (Journal No. 01 326034)
and the Danish Data Protection Agency (Journal No.
2006 41 7116).
Results
expression of hdacs and acetylated h4
in non-lymphoid cells
In addition to immunoreactivity of lymphoid cells (see
below), the antibodies against HDAC1, HDAC2 and
acetylated H4 showed nuclear labelling of epithelial
cells in the epidermis and dermal appendages. The
antibody against HDAC6 stained the cytoplasm in
these cells and also labelled the cytoplasm in endothe-
lial cells. This reactivity of non-lymphoid cells served as
useful internal controls for the immunohistochemical
reactions.
expression of hdacs and acetylated h4
in ctcl cells
In lymphoid cells, HDAC1, HDAC2 and acetylated H4
were expressed in the nuclei, whereas HDAC6 was
mainly cytoplasmic with only weak reactivity of the
nuclei in occasional cells. All four antibodies mainly
labelled neoplastic cells with atypical nuclei, whereas
small, reactive appearing lymphoid cells were negative.
Three categories were distinguished based upon
the proportion of positive cells and the intensity of
immunoreactivity, i.e. low, moderate and high (see
Materials and methods). The distribution of all CTCL
patients according to these categories is summarized in
Figure 1. Representative examples are illustrated in
Figure 2.
As shown, HDAC1 was expressed most abundan-
tly, followed by HDAC2 (P = 0.002) and HDAC6
(P < 0.0001). HDAC6 and acetylated H4 were equally
frequently expressed (P = 0.36).
expression of hdacs and acetylated h4
in ctcl categories
The relationship between immunoreactivity and CTCL
categories is summarized in Table 2. Comparisons
between indolent and aggressive cases regarding
expression of HDAC1 and HDAC6 did not show
signiﬁcant differences (P = 0.35 and P = 0.89, respec-
tively). In contrast, both HDAC2 (P = 0.001) and H4
acetylation (P = 0.03) were signiﬁcantly more com-
mon in aggressive than in indolent CTCL. For HDAC2,
55.5% of the aggressive cases showed high expression.
Conversely, among indolent CTCL, most cases (82.6%)
showed only moderate HDAC2 expression. A similar
ﬁnding was observed with H4 acetylation, where
22.2% of the aggressive cases showed high expression
compared with only 8.7% of the indolent cases. Low
H4 acetylation was observed in 30.4% of the indolent
cases, whereas only 7.4% of the aggressive cases
showed low H4 acetylation. When comparing the
expression proﬁles in patients with indolent and
aggressive subtypes, respectively, weak correlations in
the expression were observed between all four param-
eters, i.e. HDAC1, 2, 6, and acetylated H4 (data not
shown).
expression of hdacs and acetylated histone
h4 in ctcl versus survival
Overall survival was available for 59 patients. As
expected, median survival was signiﬁcantly different
between the indolent and aggressive groups, i.e.
84 months for patients with indolent CTCL compared
with 28.5 months for patients with more aggressive
disease (P < 0.0001). These results are illustrated in
Figure 3. To investigate the impact of HDACs and
acetylated H4 on survival in indolent and aggressive
CTCL we used the Cox-model to adjust for the subtype
and examined the inﬂuence of negative (score £ 2)
versus positive (score > 2) expression. For HDAC2, we
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Figure 1. Expression proﬁles of HDAC1, HDAC2, HDAC6 and H4
acetylation in cutaneous T-cell lymphoma (CTCL) (n = 73) showing
the percentage of samples in each of three categories of immuno-
reactivity (low, moderate, high). Signiﬁcant differences in expression
proﬁles are found between HDAC1 and HDAC2 (P < 0.0001) and
HDAC2 and HDAC6 (P < 0.0001), whereas HDAC6 and acetylated
H4 have similar proﬁles (P = 0.36).
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high (score > 4) expression, due to the fact that no
samples showed negative or weak expression. Survival
curves are shown in Figure 4. Cox analyses showed no
signiﬁcant inﬂuence on survival for HDAC1, HDAC2,
or acetylated H4 (see Table 3). In contrast, HDAC6
expression showed a signiﬁcant beneﬁcial inﬂuence on
survival [P = 0.04, hazard ratio (HR) 0.39, 95%
conﬁdence interval 0.16, 0.96] independent of the
CTCL subtype.
Discussion
Overexpression and improper recruitment of HDACs,
particular HDAC1 and HDAC2, have been reported
in different malignancies,
21–23,25,30,39–41 emphasizing
their role in malignant development. Although the
inﬂuence of HDAC6 in cancer is not as well investi-
gated as for HDAC1 and HDAC2, HDAC6 has been
reported to be up-regulated in oral squamous cell
carcinoma and the inhibition of HDAC6 has been
reported to induce cytotoxicity in multiple myeloma
cells as well as to reduce the amount of Bcr-Abl in
leukaemia cells.
42–44 The presumptive role of HDACs in
malignant diseases has resulted in widespread devel-
opment of HDAC inhibitors. For as yet unknown
reasons, the malignancy most sensitive to HDAC
inhibitors is CTCL.
Several clinical trials have examined the sensitivity
of CTCL to HDAC inhibitors. Vorinostat, panobinostat,
belinostat and romidepsin have all shown efﬁcacy in
CTCL with partial and complete responses. Interest-
ingly, HDAC inhibitors have demonstrated equal efﬁ-
cacy in indolent and advanced stages of CTCL in
patients who have failed prior systemic therapies. Thus,
vorinostat resulted in a response rate of 20–31% in
indolent stages (MF stage < IIB) compared with a
response rate of 25–30% in advanced stages (MF stage
IIB–IVB). All responses were partial (PR), except for
one patient with MF stage IIB, who had a complete
response (CR).
45,46 Belinostat has shown efﬁcacy in a
phase II clinical trial against recurrent and refractory
CTCL with CR in one of two patients with ALCL and
PRs in two of eight patients with MF and one of four
patients with SS.
47 Romidepsin has also shown efﬁcacy
in clinical trials. Thus, treatment with romidepsin has
resulted in an overall response rate of 31%, with PRs
reported in SS as well as plaque ⁄ patch and tumour
stages of MF. CRs have also been reported in patients
with SS together with patients with PTL, unspeciﬁed,
and CD30+ ALCL.
48–50 Finally, panobinostat has
demonstrated a response rate of six out of 10 patients
A C B
D F E
Figure 2. A, Mycosis fungoides (MF), plaque stage with high expression of HDAC1 in the nuclei of the lymphoid inﬁltrate. Note that HDAC1
is also expressed in the nuclei in epithelial cells of the epidermis. B, Cutaneous T-cell lymphoma (CTCL), unspeciﬁed with high expression of
HDAC2 in the nuclei of the neoplastic cells. C, MF, tumour stage with high HDAC6 expression in the cytoplasm. Note that HDAC6 is also
expressed in the cytoplasm of epithelial cells of the epidermis. D, MF, tumour stage, negative of HDAC6 in the lymphoid inﬁltrate. E, CTCL,
unspeciﬁed with high acetylation of histone H4. Small reactive lymphoid cells are negative. F, Precursor plasmacytoid dendritic cell neoplasm
negative for H4 acetylation.
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four PRs.
51 Although objective responses, i.e. complete
or partial, are not reached by all CTCL patients, many
still beneﬁt from treatment by achieving stable disease
and ⁄ or pruritus relief.
45–47
Only few immunohistochemical studies have exam-
ined the role of HDACs in cancer development and
these have focused mainly on solid tumours. Thus,
overexpression of HDAC1 and HDAC2 have been
reported in gastric cancer
23,39 and, in addition, HDAC2
has been associated with gastric tumour aggressive-
ness.
39 Furthermore, HDAC1, HDAC2 and HDAC3 are
up-regulated in colonic tumours compared with adja-
cent normal mucosa.
24,52,53 Up-regulation of HDAC1
and nuclear accumulation of HDAC4 have been
reported in primary and hormone refractory prostatic
cancer compared with benign prostatic hyperpla-
sia.
21,22,54 However, in another study no difference
was found in the level of HDAC1 expression between
normal and malignant prostatic epithelial cells.
55
In our study, HDAC1 was more abundantly ex-
pressed than HDAC2, HDAC6 and acetylated H4.
Acetylated H4 and HDAC6 were less expressed in
CTCL. The expression proﬁle of H4 acetylation in our
study is similar to previous ﬁndings in prostatic
cancer.
56 Further, we found signiﬁcant differences
between the expression proﬁles of HDAC1 and HDAC2.
This is in accordance with previous ﬁndings in other
types of tumour.
53,57 Our results further emphasize the
unique functions of HDAC1 and HDAC2, despite their
close sequence similarity.
The inﬂuence of HDAC1 and HDAC6 on tumour
aggressiveness is controversial. Thus, HDAC1 gene
expression was up-regulated in the indolent germinal
centre B-cell subtype of diffuse large B-cell lymphoma
compared with the more aggressive activated B-cell
and type 3 subtypes.
58,59 In contrast, in solid tumours
HDAC1 was correlated with more advanced stages of
lung cancer
60 and HDAC6 showed a directly opposite
inﬂuence in breast cancer and oral squamous cell
carcinoma.
44,61 In our study, we found no evidence for
the involvement of HDAC1 or HDAC6 in the develop-
ment of more aggressive CTCL based on their expres-
sion in indolent versus aggressive CTCL subtypes.
In contrast, we found more extensive expression of
HDAC2 in aggressive than indolent CTCL. This is in
accordance with previous ﬁndings,
24,39 indicating
possible involvement of HDAC2 in aggressive CTCL.
Several of the HDAC inhibitors in clinical trials are
hydroxamate pan-inhibitors, e.g. vorinostat, belinostat,
and panobinostat,
37,37 whereas others such as MS275,
MGCD0103 and romidepsin are subtype speciﬁc.
18
Based on the current results as well as those obtained
by Zhu et al.
24 and Song et al.,
39 it may be reasonable
to develop an HDAC2-speciﬁc inhibitor. However,
before any such decision is made, more information is
needed on the inﬂuence of HDACs in malignancies as
well as on the anti-tumour mechanism of HDAC
inhibitors and how they act in different tumours.
The inﬂuence of H4 acetylation in malignancy is
questionable. Gain of function mutations in HAT
enzymes have been identiﬁed in different types of
cancer and could in turn lead to increased histone
acetylation.
62 Furthermore, hyperacetylation of H4 is
partly caused by loss of function of HDAC1 in chronic
myeloid leukaemia.
63 Thus, H4 hyperacetylation may
be a result and not a cause of cancer development. We
found that acetylation of H4 was more pronounced in
aggressive than in indolent CTCL. In contrast, malig-
nant progression of oesophageal squamous cell carcin-
oma has been correlated to H4 hypoacetylation.
64,65 In
our study, three PTL, unspeciﬁed, showed high H4
acetylation. Interestingly, histone acetylation has been
shown to up-regulate the development of T-cell recep-
tor gamma gene recombination at least in thymo-
cytes.
66 Thus, high H4 acetylation may play a role in
lymphoma development.
When comparing the inﬂuence of HDAC expression
and acetylated H4 on survival, HDAC1 did not show
signiﬁcant results. However, a HR <1 suggests that
increased HDAC1 expression correlates with better
survival in CTCL patients (see Table 3). This is in
accordance with previous ﬁndings showing that
HDAC1 expression is associated with better survival
in breast cancer patients, at least in those with small
and well-differentiated tumours.
67,68 We could not
demonstrate that HDAC2 had an inﬂuence on survival.
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Figure 3. Overall survival of cutaneous T-cell lymphoma (CTCL)
patients (n = 59) based on indolent versus aggressive subtype.
Survival is signiﬁcantly inferior in aggressive to that in indolent
CTCL.
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inﬂuence on survival, with a HR <1, indicating a
favourable inﬂuence on survival independent of the
CTCL subtype (see Table 3). This result agrees with
previous ﬁndings showing that HDAC6 expression is
correlated with better survival in oestrogen receptor-
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Survival based on acetylated H4 in indolent CTCL
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Survival based on acetylated H4 in aggressive CTCL
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Figure 4. Overall survival of cutaneous T-cell lymphoma (CTCL) patients with either indolent or aggressive subtypes based on expression of
HDAC1, HDAC2, HDAC6, or acetylated H4. Cox analysis revealed no signiﬁcant inﬂuence of HDAC1, HDAC2, or H4 acetylation on survival.
In contrast, HDAC6 was found to have a signiﬁcantly beneﬁcial inﬂuence on survival.
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61,69 Even though
acetylated H4 does not show a signiﬁcant inﬂuence
on survival, a HR >1 indicates a possible negative
inﬂuence of H4 acetylation on survival (see Table 3).
This is in contrast to previous ﬁndings showing better
prognosis for patients with a high level of acetylated
H4.
65
In conclusion, we have found that overexpression of
HDAC6 had a beneﬁcial inﬂuence on survival and that
this was independent of the CTCL subtype. Further,
high expression of HDAC2 and acetylated H4 was more
common in aggressive than in indolent CTCL.
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